JMP Views Positive Phase 3 Data Equivalent To 'Schizophrenia Blockbuster' For This Stock

  • JMP Securities raised the price target on Karuna Therapeutics Inc KRTX from $175 to $190 with a Market Outperform rating. 
  • The analysts note Karuna as the top pick ahead of imminent Phase 3 results for KarXT in schizophrenia.
  • They note that results from the Phase 3 EMERGENT-2 trial are expected within weeks (estimated mid-July to mid-August), with high confidence levels (probability of success ~80%). 
  • "Looking ahead to KarXT's commercial potential, we believe that in addition to robust efficacy, differentiating attributes that can drive adoption are the novel mechanism of action and favorable safety/tolerability profile," JMP writes.
  • Also See: Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial.
  • "We also believe that the opportunity for the candidate in additional indications, specifically ADP, remains underappreciated, and positive schizophrenia results should have broader positive read-through," it added.
  • The increased price target reflects higher U.S. peak penetration sales in schizophrenia (from $1.9 billion in 2028 to around $2.5 billion in 2030) and an increased probability of approval in Alzheimer's disease psychosis (ADP) (from 50% to 60%). 
  • Price Action: KRTX shares closed up 2.45% at $120.65 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CarePrice TargetAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!